
A new recall of injected penicillin may put gains against syphilis in peril
The news – the latest twist in a drug shortage that began in 2023 – follows a July 10 recall of certain lots of Bicillin L-A that were found to be contaminated with floating particles. Pfizer says it has not received any reports of adverse events related to the recalled shots.
'We have identified the root cause to be associated with stoppers supplied from an external vendor and are implementing the appropriate corrective and preventative actions,' the company said in a statement, adding that it places the utmost emphasis on patient safety. 'We fully recognize the importance of this medicine for patients and are working as quickly as possible to resolve the matter.'
Benzathine penicillin G, sold as Bicillin, is used to treat a number of common bacterial infections, such as strep throat, in adults and children. Because one shot can last up to two weeks, it's especially helpful for people who can't swallow pills or may not be able to remember to take them. In most cases, however, if the shots aren't available, doctors can turn to alternatives like the antibiotic doxycycline.
But benzathine penicillin G is the only product that's approved and recommended to treat the sexually transmitted infection syphilis during pregnancy. If the infection is caught early, a single injection can keep the infection from spreading to a newborn, a condition called congenital syphilis.
Without treatment, syphilis during pregnancy can cause miscarriages and stillbirths. It can also be fatal for infants. Syphilis can also cause vision and hearing problems in babies as well as deformities of the bones and teeth.
As rates of syphilis rose in adults, more babies became infected, too. Over the past decade, rates of congenital syphilis have increased tenfold in the United States, from 335 in 2012 to more than 3,800 in 2023, according to data from the US Centers for Disease Control and Prevention.
'We're in the midst of a congenital syphilis crisis, and we've been calling for an emergency declaration for congenital syphilis for years,' said Dr. Jeffrey Klausner, a professor of clinical population and public health sciences at the University of Southern California's Keck School of Medicine. 'This threatens to make that even worse.'
The shot has been a key part of the strategy that some states have been using to quell rising rates of congenital syphilis.
Because too many pregnant patients infected with syphilis weren't making it into basic primary care, there's been a push in states including New Mexico and Minnesota to test all pregnant women for syphilis at multiple stages of pregnancy and whenever they show up in emergency rooms or urgent care clinics.
After an initial positive test, providers are encouraged to treat a pregnant patient with a shot of long-acting penicillin at the same visit, without waiting for the results of a second confirmatory test.
This push for one-stop testing and treatment has already had an effect.
'With the latest release of data, we saw a slowing of rates, which was really exciting,' said a CDC official familiar with the data who asked not to be named because they weren't authorized to speak to the media. That progress is the result of hard work bringing awareness to controlling syphilis and congenital syphilis, the official said.
Bicillin L-A most recently went into shortage in 2023. During that time, the US Food and Drug Administration has allowed imports of two equivalent products, a French drug called Extencilline, and Lentocilin, which is imported from Portugal and sold by entrepreneur Mark Cuban's Cost Plus Drugs. These imports continue to be authorized.
Those forms of the medication are trickier to use, said Erin Fox, associate chief pharmacy officer at the University of Utah Health.
'In a health system, it's very hard to use imported products,' she said. The bar coding on the drugs isn't recognized by most hospital systems, and there may be differences in how the products are mixed and diluted, which can be confusing.
Her hospital has been handling the shortage by being judicious about who gets Bicillin shots. It hasn't had to use an imported products yet.
Pfizer has also been working to boost its supply. The company stopped shipping pediatric doses in 2023 and instead focused on making adult doses to prioritize supply for pregnant patients. According to the FDA's drug shortage website, Pfizer expected to have a delivery of pediatric doses available in October.
Now, the company has advised customers that it will give an update on the Bicillin supply no later than mid-August. Until stock has fully recovered, Pfizer said, it will ration available supplies of the shots. Providers will have to fill out medical request forms, and the company will send supplies on a per-patient basis.
Sterile injectable products like Bicillin are especially vulnerable to shortages because they have a more complex manufacturing process than pills and tend to be prone to quality control issues. In this case, Pfizer is the sole supplier of Bicillin for the US.
The nonprofit National Coalition of STD Directors said it's gathering information from members to understand how far-reaching the impact of the recall may be.
One of its committees met Monday, and all of the participants were in the process of returning Bicillin doses to Pfizer. One state returned about 800 vials, 'so we expect to hear this is widespread,' said Elizabeth Finley, senior director of communications and programs for the organization.
'We had a small reprieve for about, maybe a year, in terms of steady supply. And now this is just a complete kick in the teeth and really threatens our ability to prevent and control syphilis,' Klausner said.
The CDC had previously posted recommendations for caring for syphilis patients during the shortage, but that information has since been taken down. Fox, who investigates drug shortages for the Association of Health Systems Pharmacists, said she has asked the agency to repost it but hasn't received a response.
CDC staffers who work on syphilis control were hit hard by recent government layoffs, although about 200 were reinstated in June. Federal funding cuts have also hampered state and local efforts to control sexually transmitted infections.
The FDA updated its drug shortage page with links to Pfizer's recent guidance but has not posted Pfizer's recall announcement.
A spokesperson for the US Department of Health and Human services referred questions about the recall and potential supply problems to Pfizer.
'I am concerned though that now, with a cut in funds to national and local STD programs, that we will start to see a drop in testing for syphilis,' the CDC official said. 'Cuts to Medicaid and Medicare, as well as other programs, will be devastating for syphilis control.'
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Pfizer Stock: Analyst Estimates & Ratings
With a market cap of $138.2 billion, Pfizer Inc. (PFE) is a leading global biopharmaceutical company headquartered in New York City. Founded in 1849, Pfizer discovers, develops and manufactures medicines and vaccines across a broad range of therapeutic areas, including oncology, immunology, rare diseases, cardiology, endocrinology and vaccines. Shares of this pharmaceutical giant have underperformed the broader market over the past year. PFE has declined 21% over this time frame, while the broader S&P 500 Index ($SPX) has rallied nearly 17.1%. In 2025, PFE stock is down 8.4%, compared to SPX's 8.6% rise on a YTD basis. More News from Barchart Tesla Just Signed a Chip Supply Deal with Samsung. What Does That Mean for TSLA Stock? Dear Microsoft Stock Fans, Mark Your Calendars for Aug. 1 Is Lucid Motors Stock a Buy, Sell, or Hold for July 2025? Tired of missing midday reversals? The FREE Barchart Brief newsletter keeps you in the know. Sign up now! Zooming in, PFE has also trailed the Invesco Pharmaceuticals ETF (PJP), which has fallen 2.7% over the past year and has surged 1.3% in 2025 On July 24, Pfizer announced a global (excluding China) licensing agreement with 3SBio for exclusive rights to develop, manufacture, and commercialize SSGJ-707, a bispecific antibody targeting PD-1 and VEGF. The deal strengthens Pfizer's oncology pipeline and reinforces its position in innovative cancer research. However, its shares dropped 2.2% in the next trading session amid macroeconomic headwinds. For the current fiscal year, ending in December, analysts expect PFE's EPS to decline 1.3% year over year to $3.07 on a diluted basis. The company's earnings surprise history is impressive. It beat the consensus estimate in each of the last four quarters. Among the 22 analysts covering PFE stock, the consensus is a 'Moderate Buy.' That's based on six 'Strong Buy' ratings, one 'Moderate Buy,' 14 'Holds,' and one 'Strong Sell.' This configuration is less bullish than three months ago, when seven analysts suggested a 'Strong Buy.' On April 30, UBS Group AG (UBS) analyst Trung Huynh raised Pfizer's price target from $24 to $25 while maintaining a 'Neutral' rating. Despite mixed revenue performance, the analyst highlighted Pfizer's significant cost savings as a positive factor. The mean price target of $27.81 represents a 14.4% premium to PFE's current price levels. The Street-high price target of $33 suggests an ambitious upside potential of 35.7%. On the date of publication, Kritika Sarmah did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data


New York Times
18 hours ago
- New York Times
3 Out of 5 Liver Cancer Cases Are Preventable, Study Finds
Liver cancer kills more than 700,000 people a year. But three in five cases could be prevented, according to a comprehensive analysis published on Monday in the journal Lancet. The research found that prevention could be accomplished by addressing the disease's major causes: hepatitis B, hepatitis C, alcohol-associated liver disease and liver disease linked to metabolic risk factors like obesity. With nearly 900,000 new cases globally each year, liver cancer is the sixth most common cancer and the third leading cause of death from cancer. If cases continue to rise at the current rate, the number of new annual diagnoses will almost double, rising to 1.5 million globally in 2050, the study predicted. The researchers estimated that liver disease from alcohol use and metabolic dysfunction together would account for nearly one-third of new liver cancer cases by then. The findings align with what liver specialists have seen in their clinics for years. 'Liver cancer is common, it causes immense suffering and death, and the saddest part for me as a physician is that most of the cases are preventable,' said Dr. Brian P. Lee, an associate professor of medicine at the Keck School of Medicine at the University of Southern California, who was not involved in the study. Improved screening, vaccination and treatment in recent years have helped stem viral hepatitis, especially in the United States. But the threat of liver cancer from heavy alcohol use and metabolic dysfunction-associated steatotic liver disease, or MASLD, formerly known as nonalcoholic fatty liver disease, 'has been underrecognized and underestimated,' said Dr. Ahmed Kaseb, a professor of gastrointestinal medical oncology at the University of Texas MD Anderson Cancer Center, who was not associated with the study. A 'Highway' to Liver Cancer A vast majority of liver cancers arise in people with cirrhosis, said Dr. Hashem El-Serag, the chair of the department of medicine at Baylor College of Medicine in Texas and one of the authors of the new study. Cirrhosis, or advanced and largely irreversible scarring of the liver, damages healthy tissue and prevents the organ from working normally. Want all of The Times? Subscribe.


Newsweek
a day ago
- Newsweek
Wearable Sensor Will Improve Bipolar Disorder Treatment
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. A wearable sensor could make tracking medication levels much easier for people living with bipolar disorder, eliminating the need for blood draws and lab analyses. The first-of-its-kind device could vastly improve treatment, convenience and drug safety for millions of patients who take lithium—a type of mood stabilizer—for bipolar disorder. While lithium is highly effective, it must be administered precisely and needs regular monitoring. Too low a dose, and the treatment doesn't work—but too high a dose can be toxic to patients, with the potential to cause kidney and thyroid damage, or even death. In addition, the correct dose of lithium depends on the individual. In their study, the researchers from the University of Southern California (USC) argue that sweat is an easier alternative to blood for lithium tracking because it can both be collected noninvasively and reflect lithium concentrations in real time. Printed and flexible wearable sensor for lithium monitoring in sweat being stuck to skin. Printed and flexible wearable sensor for lithium monitoring in sweat being stuck to skin. Mohammad Shafiqul Islam, Khan Lab, USC Viterbi School of Engineering Bipolar disorder affects around 5.7 million adult Americans, or about 2.6 percent of the U.S. population aged 18 and older each year, according to the National Institute of Mental Health. The current method of laboratory-based blood draws for tracking can be time-consuming, inconvenient and painful. "While past approaches required collecting body fluids for lab testing or using multiple devices—such as stimulating sweat, applying a color-changing lithium sensor, and then photographing it to estimate levels—our wearable simplifies everything," USC electrical and computer engineer professor Yasser Khan told Newsweek. "It collects sweat and measures lithium levels in one fully integrated, non-invasive device." The newly designed wearable includes a skin-safe, electrical current-based system to induce sweat without requiring physical exertion. In just minutes, the device can collect the data and transmit it directly to a smartphone app, allowing people to track their lithium levels from home (or wherever they might be). This reduces the need for more invasive tracking, similarly to a glucose monitor reducing the need for people with diabetes to check their blood glucose levels with a finger prick test, though they work slightly differently. "Unlike continuous glucose monitors (CGMs) that rely on a needle under the skin, our wearable is sweat-based and sticks on the skin like a simple bandage. While CGMs don't require a sample collection step, our device needs to first stimulate sweat before measuring lithium levels, adding one step, but avoiding needles entirely," Khan explained. The wearable sensor to track lithium has been made possible by the innovative use of something called 'organic electrochemical transistors' (OECTs) specifically designed for lithium detection, according to the researchers. OECTs are electronic devices that respond to ionic signals in liquid, converting them into readable electronic data. Unlike conventional OECTs, the sensor developed at USC features a fully printed OECT using a new material formulation tailored to detect lithium ions specifically. "We developed the entire lithium monitoring system—from the OECT-based sensor patch and on-demand sweat induction to the readout electronics and smartphone app—using a simple, scalable and cost-effective fabrication process," said study author and doctoral student Mohammad Shafiqul Islam in a statement. "Our goal was to make lithium tracking as easy and comfortable for patients as checking a daily fitness tracker." This makes it the first OECT-based lithium sensor to be entirely printed, which is hoped to pave the way for affordable and scalable production. In partnership with psychiatrist Adam Frank at Keck School of Medicine, the device has already been tested by those of his patients taking lithium—gaining positive feedback. Sweat samples were collected using the wearable device and lithium measurements were successfully matched against values derived from bulky commercial sensors. "We conducted a pilot study with three patients, focusing primarily on showcasing the wearable's development. All participants appreciated the convenience of using a simple at-home device compared to frequent lab visits for blood draws," Khan told Newsweek. "The wearable measures lithium levels and displays the concentration on a smartphone, making it accessible to both patients and physicians. Over time, patients can better understand what works for them—for example, one participant noted that a concentration around 0.4 mM was effective. This kind of personalized insight is one of the key benefits of wearable technologies." The new device is hoped to improve safety by allowing for medication dose adjustments that avoid side effects and potential medication toxicity. Keen to keep the momentum going for those living with bipolar disorder, Khan said: "This is a market-ready technology that now needs to be translated from the lab into a consumer device. To reach widespread adoption, a larger clinical study involving hundreds of patients will be essential." The team plans to develop more advanced wearable systems powered by AI to automatically adjust lithium dosage and achieve optimal therapeutic benefits without causing lithium toxicity. Do you have a health story to share with Newsweek? Do you have a question about bipolar disorder? Let us know via health@ Reference Islam, M. S., Kunnel, B. P., Ferdoushi, M., Hassan, M. F., Cha, S., Cai, W., Frank, A., & Khan, Y. (2025). Wearable organic-electrochemical-transistor-based lithium sensor for precision mental health. Device.